Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) show potent efficacy in several ALK-driven tumors, but the development of resistance limits their long-term clinical impact. Although resistance mechanisms have been studied extensively in ALK-driven non-small cell lung cancer, they are poorly understood in ALK-driven anaplastic large cell lymphoma (ALCL). Here, we identify a survival pathway supported by the tumor microenvironment that activates phosphatidylinositol 3-kinase γ (PI3K-γ) signaling through the C-C motif chemokine receptor 7 (CCR7). We found increased PI3K signaling in patients and ALCL cell lines resistant to ALK TKIs. PI3Kγ expression was predictive of a lack of response to ALK TKI in patients with ALCL. Expression of CCR7, PI3Kγ, and PI3Kδ were up-regulated during ALK or STAT3 inhibition or degradation and a constitutively active PI3Kγ isoform cooperated with oncogenic ALK to accelerate lymphomagenesis in mice. In a three-dimensional microfluidic chip, endothelial cells that produce the CCR7 ligands CCL19/CCL21 protected ALCL cells from apoptosis induced by crizotinib. The PI3Kγ/δ inhibitor duvelisib potentiated crizotinib activity against ALCL lines and patient-derived xenografts. Furthermore, genetic deletion of CCR7 blocked the central nervous system dissemination and perivascular growth of ALCL in mice treated with crizotinib. Thus, blockade of PI3Kγ or CCR7 signaling together with ALK TKI treatment reduces primary resistance and the survival of persister lymphoma cells in ALCL.

Candiolo Cancer Institute FPO IRCCS Candiolo Torino 10060 Italy

Dana Farber Cancer Institute Boston MA 02115 USA

Department of Biological Engineering Massachusetts Institute of Technology Cambridge MA 02139 USA

Department of Mechanical and Aerospace Engineering Politecnico of Torino Torino 10129 Italy

Department of Mechanical Engineering Massachusetts Institute of Technology Cambridge MA 02139 USA

Department of Medical Science University of Torino Torino 10126 Italy

Department of Medicine and Surgery University of Milan Bicocca Monza 20900 Italy

Department of Molecular Biotechnology and Health Sciences University of Torino Torino 10126 Italy

Department of Oncology University of Torino Orbassano Torino 10043 Italy

Department of Pathology Boston Children's Hospital and Harvard Medical School Boston MA 02115 USA

Department of Pathology Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA

Department of Pathology Cornell University New York NY 10121 USA

Department of Pediatric and Adolescent Oncology Gustave Roussy Cancer Center Paris Saclay University Villejuif 94805 France

Department of Pre Clinical Development Catapult Therapeutics B 5 8243 RC Lelystad Netherlands

Division of Cellular and Molecular Pathology Department of Pathology University of Cambridge Addenbrooke's Hospital Cambridge CB2 0QQ UK

Faculty of Medicine Masaryk University Brno 601 77 Czech Republic

Harvard Medical School Boston MA 02115 USA

Université Paris Saclay INSERM U1015 Villejuif 94805 France

University Medical Center Göttingen 37075 Göttingen Germany

000      

00000naa a2200000 a 4500

001      

bmc23010982

003      

CZ-PrNML

005      

20230801132739.0

007      

ta

008      

230718s2023 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1126/scitranslmed.abo3826 $2 doi

035    __

$a (PubMed)37379367

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Mastini, Cristina $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy $1 https://orcid.org/0000000153802611

245    10

$a Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma / $c C. Mastini, M. Campisi, E. Patrucco, G. Mura, A. Ferreira, C. Costa, C. Ambrogio, G. Germena, C. Martinengo, S. Peola, I. Mota, E. Vissio, L. Molinaro, M. Arigoni, M. Olivero, R. Calogero, N. Prokoph, F. Tabbò, B. Shoji, L. Brugieres, B. Geoerger, SD. Turner, C. Cuesta-Mateos, D. D'Aliberti, L. Mologni, R. Piazza, C. Gambacorti-Passerini, GG. Inghirami, V. Chiono, RD. Kamm, E. Hirsch, R. Koch, DM. Weinstock, JC. Aster, C. Voena, R. Chiarle

520    9_

$a Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) show potent efficacy in several ALK-driven tumors, but the development of resistance limits their long-term clinical impact. Although resistance mechanisms have been studied extensively in ALK-driven non-small cell lung cancer, they are poorly understood in ALK-driven anaplastic large cell lymphoma (ALCL). Here, we identify a survival pathway supported by the tumor microenvironment that activates phosphatidylinositol 3-kinase γ (PI3K-γ) signaling through the C-C motif chemokine receptor 7 (CCR7). We found increased PI3K signaling in patients and ALCL cell lines resistant to ALK TKIs. PI3Kγ expression was predictive of a lack of response to ALK TKI in patients with ALCL. Expression of CCR7, PI3Kγ, and PI3Kδ were up-regulated during ALK or STAT3 inhibition or degradation and a constitutively active PI3Kγ isoform cooperated with oncogenic ALK to accelerate lymphomagenesis in mice. In a three-dimensional microfluidic chip, endothelial cells that produce the CCR7 ligands CCL19/CCL21 protected ALCL cells from apoptosis induced by crizotinib. The PI3Kγ/δ inhibitor duvelisib potentiated crizotinib activity against ALCL lines and patient-derived xenografts. Furthermore, genetic deletion of CCR7 blocked the central nervous system dissemination and perivascular growth of ALCL in mice treated with crizotinib. Thus, blockade of PI3Kγ or CCR7 signaling together with ALK TKI treatment reduces primary resistance and the survival of persister lymphoma cells in ALCL.

650    _2

$a lidé $7 D006801

650    _2

$a zvířata $7 D000818

650    _2

$a myši $7 D051379

650    _2

$a krizotinib $x farmakologie $x terapeutické užití $7 D000077547

650    _2

$a tyrosinkinasové receptory $x metabolismus $7 D020794

650    _2

$a anaplastická lymfomová kináza $7 D000077548

650    _2

$a receptory CCR7 $x genetika $7 D054400

650    _2

$a inhibitory tyrosinkinasy $7 D000092004

650    12

$a nemalobuněčný karcinom plic $x farmakoterapie $7 D002289

650    _2

$a endoteliální buňky $x metabolismus $7 D042783

650    _2

$a fosfatidylinositol-3-kinasy $7 D019869

650    12

$a nádory plic $x farmakoterapie $7 D008175

650    _2

$a tyrosinkinasy $7 D011505

650    _2

$a inhibitory proteinkinas $x farmakologie $x terapeutické užití $7 D047428

650    12

$a anaplastický velkobuněčný lymfom $x farmakoterapie $x genetika $x patologie $7 D017728

650    _2

$a nádorové buněčné linie $7 D045744

650    _2

$a nádorové mikroprostředí $7 D059016

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

655    _2

$a Research Support, N.I.H., Extramural $7 D052061

700    1_

$a Campisi, Marco $u Dana Farber Cancer Institute, Boston, MA 02115, USA $u Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA $u Department of Mechanical and Aerospace Engineering, Politecnico of Torino, Torino 10129, Italy $1 https://orcid.org/0000000292885285

700    1_

$a Patrucco, Enrico $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy $1 https://orcid.org/0000000180605058

700    1_

$a Mura, Giulia $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy

700    1_

$a Ferreira, Antonio $u Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston MA 02115, USA $1 https://orcid.org/0000000346148580

700    1_

$a Costa, Carlotta $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy

700    1_

$a Ambrogio, Chiara $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy $1 https://orcid.org/000000034122701X

700    1_

$a Germena, Giulia $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy $1 https://orcid.org/0000000170054272

700    1_

$a Martinengo, Cinzia $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy

700    1_

$a Peola, Silvia $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy

700    1_

$a Mota, Ines $u Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA $1 https://orcid.org/0000000315237134

700    1_

$a Vissio, Elena $u Department of Oncology, University of Torino, Orbassano, Torino 10043, Italy $1 https://orcid.org/0000000239480641

700    1_

$a Molinaro, Luca $u Department of Medical Science, University of Torino, Torino 10126, Italy

700    1_

$a Arigoni, Maddalena $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy $1 https://orcid.org/0000000346293841

700    1_

$a Olivero, Martina $u Department of Oncology, University of Torino, Orbassano, Torino 10043, Italy $u Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino 10060, Italy

700    1_

$a Calogero, Raffaele $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy

700    1_

$a Prokoph, Nina $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK $1 https://orcid.org/0000000264299895

700    1_

$a Tabbò, Fabrizio $u Department of Pathology, Cornell University, New York NY 10121, USA $1 https://orcid.org/0000000185252992

700    1_

$a Shoji, Brent $u Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston MA 02115, USA $1 https://orcid.org/0000000182887589

700    1_

$a Brugieres, Laurence $u Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif 94805, France $1 https://orcid.org/0000000277986651

700    1_

$a Geoerger, Birgit $u Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif 94805, France $u Université Paris-Saclay, INSERM U1015, Villejuif 94805, France $1 https://orcid.org/0000000343613643

700    1_

$a Turner, Suzanne D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK $u Faculty of Medicine, Masaryk University, Brno 601 77, Czech Republic $1 https://orcid.org/0000000284394507

700    1_

$a Cuesta-Mateos, Carlos $u Department of Pre-Clinical Development, Catapult Therapeutics B.V., 8243 RC, Lelystad, Netherlands

700    1_

$a D'Aliberti, Deborah $u Department of Medicine and Surgery, University of Milan-Bicocca, Monza 20900, Italy $1 https://orcid.org/0009000537609391

700    1_

$a Mologni, Luca $u Department of Medicine and Surgery, University of Milan-Bicocca, Monza 20900, Italy $1 https://orcid.org/0000000263655149

700    1_

$a Piazza, Rocco $u Department of Medicine and Surgery, University of Milan-Bicocca, Monza 20900, Italy $1 https://orcid.org/0000000341989620

700    1_

$a Gambacorti-Passerini, Carlo $u Department of Medicine and Surgery, University of Milan-Bicocca, Monza 20900, Italy

700    1_

$a Inghirami, Giorgio G $u Department of Pathology, Cornell University, New York NY 10121, USA

700    1_

$a Chiono, Valeria $u Department of Mechanical and Aerospace Engineering, Politecnico of Torino, Torino 10129, Italy $1 https://orcid.org/0000000320677732

700    1_

$a Kamm, Roger D $u Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA $u Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA $1 https://orcid.org/000000027232304X

700    1_

$a Hirsch, Emilio $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy $1 https://orcid.org/0000000290736024

700    1_

$a Koch, Raphael $u Dana Farber Cancer Institute, Boston, MA 02115, USA $u Harvard Medical School, Boston, MA 02115, USA $u University Medical Center Göttingen, 37075 Göttingen, Germany $1 https://orcid.org/0000000220185685

700    1_

$a Weinstock, David M $u Dana Farber Cancer Institute, Boston, MA 02115, USA $u Harvard Medical School, Boston, MA 02115, USA $1 https://orcid.org/0000000287243907

700    1_

$a Aster, Jon C $u Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston MA 02115, USA

700    1_

$a Voena, Claudia $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy $1 https://orcid.org/0000000213241431

700    1_

$a Chiarle, Roberto $u Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino 10126, Italy $u Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA $1 https://orcid.org/0000000315648531

773    0_

$w MED00177505 $t Science translational medicine $x 1946-6242 $g Roč. 15, č. 702 (2023), s. eabo3826

856    41

$u https://pubmed.ncbi.nlm.nih.gov/37379367 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20230718 $b ABA008

991    __

$a 20230801132735 $b ABA008

999    __

$a ok $b bmc $g 1963418 $s 1197247

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 15 $c 702 $d eabo3826 $e 20230628 $i 1946-6242 $m Science translational medicine $n Sci Transl Med $x MED00177505

LZP    __

$a Pubmed-20230718